Book a demo

Chemical intelligence powered by cypris.ai

Methylatropine nitrate

[(1R,5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate nitrate · also: Ekomine, Europen, Metanite, Eumydrin, Eumidrina, Eumydrine

FormulaC18H26N2O6
Mol. weight366.414
PubChem CID657381
InChIKeyNEDVJZNVOSNSHF-ZNHDNBJUSA-N
SMILESC[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[N+](=O)([O-])[O-]
1,777Patents
437Research papers
70Patents - last 3 years
3Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Theravance Biopharma R&D IP LLC170
2Innoviva Inc104
3MedImmune LLC84
4Glaxo Group Ltd63
5Cydex Pharmaceuticals Inc44
6Encysive Pharmaceuticals Inc36
7Chase Pharmaceuticals Corp31
8Merck Sharp & Dohme LLC30
9PTC Therapeutics Inc28
10Stemline Therapeutics Inc26

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61PTherapeutic activity (drug indications)1,184
2A61KMedicinal preparations1,017
3C07DHeterocyclic compounds595
4C07KPeptides212
5A61MDevices for introducing media into the body110
6C12NMicroorganisms, enzymes105
7C07CAcyclic and carbocyclic compounds80
8G01NInvestigating / analysing materials80
9Y02AClimate change adaptation80
10C08LPolymer compositions (blends)69

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Most-cited patents

Patents ranked by forward citations reveal the foundational inventions the field continues to build on.

TitleYearAssigneeCited by
Nejiyamas Ekomine Neji1983ROCKFORD HEADED PRODUCTS0

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#Research topicPapers
1Heart Rate Variability and Autonomic Control2
2Neuroscience of respiration and sleep2
3Epilepsy research and treatment1
4Medicinal Plant Extracts Effects1
5MicroRNA in disease regulation1
6Neuroscience and Neuropharmacology Research1
7Receptor Mechanisms and Signaling1
8Veterinary Pharmacology and Anesthesia1

Technology trend analysis

Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.

See Cypris in action

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1Bo ÅhrénLund University8
2David H. OverstreetUniversity of California, Los Angeles6
3Hugo Celso Dutra de SouzaUniversidade de São Paulo6
4Anton SimeonovNational Center for Advancing Translational Sciences5
5Hélio César SalgadoUniversidade de São Paulo5
6Ajit JadhavNational Center for Advancing Translational Sciences4
7Cândido Celso CoimbraUniversidade Federal de Minas Gerais4
8Daniel TuckerPerformance Communications4
9Jeffrey M. WitkinWalter Reed Army Institute of Research4
10John R. MartinA.T. Still University4

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

TitleYearCited byTopic
Role of the Parasympathetic System in Airway Obstruction Due to Emphysema1984262Asthma and respiratory diseases
Selective hepatic vagotomy blocks pancreatic glucagon's satiety effect1983134Gastrointestinal motility and disorders

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and weight of Methylatropine nitrate?

Methylatropine nitrate has the molecular formula C18H26N2O6 and a molecular weight of 366.414. Its canonical IUPAC name is [(1R,5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate nitrate.

Which organizations have filed the most patents related to Methylatropine nitrate?

The leading patent assignees are Theravance Biopharma R&D IP LLC with 170 patents, Innoviva Inc with 104 patents, and MedImmune LLC with 84 patents. Other significant assignees include Glaxo Group Ltd, Cydex Pharmaceuticals Inc, and Encysive Pharmaceuticals Inc.

What are the primary patent classification areas for Methylatropine nitrate patents?

The most common CPC subclasses are A61P (therapeutic applications) with 1184 patents, A61K (pharmaceutical preparations) with 1017 patents, and C07D (organic chemistry compounds) with 595 patents. These are followed by C07K, A61M, and C12N subclasses.

What research topics are associated with Methylatropine nitrate publications?

Published research on Methylatropine nitrate covers Heart Rate Variability and Autonomic Control, Neuroscience of respiration and sleep, Epilepsy research and treatment, Veterinary Pharmacology and Anesthesia, and Receptor Mechanisms and Signaling, among others.

What is the patent filing trend for Methylatropine nitrate in recent years?

Patent filings have declined in recent years, from 64 patents in 2016 to 23 in 2025. The last three years show a continued downward trend with 38 patents in 2022, 43 in 2023, and 32 in 2024, representing a total of 70 patents filed in the last three years.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial